Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Changqing Technology (603125.SH) has completed the debugging of production processes and machinery for its Phase Seven project, which is now ready for formal production, aligning with the company's strategic development needs and benefiting all shareholders [1] Group 1 - The Phase Seven project production line will expand the company's capacity and enhance its product matrix [1] - The project strengthens the company's key material layout in the high polymer new materials industry [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏常青树新材料科技股份有限公司 证券代码：603125 证券简称：常青科技 公告编号：2025-077 江苏常青树新材料科技股份有限公司 关于七期（特种高分子单体二期）项目投产的公告 江苏常青树新材料科技股份有限公司（以下简称"公司"）以自有资金投资 建设的七期（特种高分子单体二期）项目（以下简称"七期项目"）已于 2025 年 5 月底试生产，具体内容详见公司于 2025 年 5 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于七期（特种高分子单体二期）项目试生产的公 告》（公告编号：2025-042）。 经过前期的试生产，截至本公告日，七期项目已完成对生产工艺及机器设备 的调试，具备正式投产条件。七期项目生产线投产后将扩大公司产能、完善公司 产品矩阵，强化公司在高分子新材料产业的关键材料布局，符合公司战略发展需 要和全体股东的利益。七期项目生产线投产后的预期效益可能受宏观经济与市场 需求变化等因素的影响，敬请广大投资者谨慎决策，注意投资风险。 ...

江苏常青树新材料科技股份有限公司 证券代码：603125 证券简称：常青科技 公告编号：2025-078 江苏常青树新材料科技股份有限公司 关于使用暂时闲置自有资金进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏常青树新材料科技股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的第二届董事会第十次会议及第二届监事会第九次会议，审议通过了《关 于公司拟使用暂时闲置自有资金进行现金管理的议案》，同意公司在不超过人民 币 50,000 万元的额度内使用闲置自有资金进行现金管理，上述额度自董事会审 议通过之日起 12 个月内可滚动计算。该事项在董事会审批权限内，无须提交股 东会审议。 二、截至本公告日，连续 12 个月内滚动使用自有资金现金管理的情况 一、使用闲置自有资金进行现金管理到期赎回的情况 序 号 受托方 产品名称 产品性质 投资 金额 （万元） 预计年 化收益 率 产品 期限 起息日 到期日 实际 收益 （万元） 1. 中国光大 银行股份 有限公司 2025年挂钩汇率对公 ...

Core Viewpoint - Changqing Technology (603125.SH) has announced that its Phase Seven project (Special High Polymer Monomer Phase II) has commenced trial production by the end of May 2025, marking a significant step in expanding its production capacity and enhancing its product matrix in the high polymer new materials industry [1] Group 1 - The Phase Seven project has completed the debugging of production processes and machinery, meeting the conditions for formal production [1] - The production line's launch will enhance the company's capacity and strengthen its strategic positioning in key materials within the high polymer new materials sector [1] - The project aligns with the company's strategic development needs and benefits all shareholders [1]

人民财讯12月22日电，常青科技（603125）12月22日公告，公司以自有资金投资建设的七期(特种高分 子单体二期)项目(下称"七期项目")已于2025年5月底试生产，经过前期的试生产，截至目前，七期项目 已完成对生产工艺及机器设备的调试，具备正式投产条件。 ...

Core Viewpoint - Changqing Technology (603125.SH) has announced that its Phase Seven project, focused on special high polymer monomers, has commenced trial production by the end of May 2025, marking a significant step in its operational capacity and strategic development [1] Group 1 - The Phase Seven project has completed the debugging of production processes and machinery, meeting the conditions for formal production [1] - The production line's launch will expand the company's capacity and enhance its product matrix, reinforcing its position in the high polymer new materials industry [1] - The project aligns with the company's strategic development needs and benefits all shareholders [1]

Group 1 - The core viewpoint of the article is that Changqing Technology (603125) is progressing as planned with its "special polymer materials additives and electronic specialty materials manufacturing project" [1] - The company has indicated that relevant production lines have been gradually completed and are being put into use [1]

光大证券股份有限公司 关于江苏常青树新材料科技股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 保荐人 二〇二五年十二月 江苏常青树新材料科技股份有限公司 发行保荐书 保荐人及保荐代表人声明 光大证券股份有限公司及本项目的保荐代表人马志鹏、钱林凯根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、《上市公司证券发行注册管理办法》（以下简称《注册管理 办法》）、《证券发行上市保荐业务管理办法》（以下简称《保荐办法》）等有 关法律、法规和中国证券监督管理委员会（以下简称中国证监会）的有关规定， 诚实守信，勤勉尽责，严格按照依法制定的业务规则、行业执业规范和道德准则 出具发行保荐书，并保证所出具文件的真实性、准确性和完整性。 如无特别说明，本发行保荐书中的简称或名词的释义与《江苏常青树新材料 科技股份有限公司向不特定对象发行可转换公司债券募集说明书》中相同。 3-1-1 江苏常青树新材料科技股份有限公司 发行保荐书 第一节 本次证券发行基本情况 一、保荐人指定保荐代表人及其执业情况 光大证券股份有限公司（以下简称"光大证券"或"保荐人"）接受江苏常 青 ...

国浩律师（上海）事务所 关 于 之 补充法律意见书（一） 上海市静安区山西北路 99 号苏河湾中心 25-28 层 邮编：200048 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 2025 年 12 月 江苏常青树新材料科技股份有限公司 向不特定对象发行可转换公司债券 国浩律师（上海）事务所 补充法律意见书（一） 国浩律师（上海）事务所 关于江苏常青树新材料科技股份有限公司 向不特定对象发行可转换公司债券之 补充法律意见书（一） 致：江苏常青树新材料科技股份有限公司 国浩律师（上海）事务所接受江苏常青树新材料科技股份有限公司委托， 担任发行人申请向不特定对象发行可转换公司债券并在上海证券交易所上市事 宜的专项法律顾问。 （二） 本所律师同意将本补充法律意见书作为发行人本次发行所必备的 法律文件，随同其他申报材料一同上报，并愿 ...